Since the publication of the Revised European-American Classification of Lymphoid Neoplasms
in 1994, subsequent updates of the classification of lymphoid neoplasms have been …

Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of …

Background Patients with large B-cell lymphoma (LBCL) primary refractory to or relapsed
within 12 months of first-line therapy are at high risk for poor outcomes with current standard of …

Background Based on the encouraging activity and manageable safety profile observed in
a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of …

Background Patient outcomes are poor for aggressive B-cell non-Hodgkin’s lymphomas not
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …

Background Activating mutations of EZH2, an epigenetic regulator, are present in approximately
20% of patients with follicular lymphoma. We investigated the activity and safety of …

Background The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma
(DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor cells. …

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). …

… Bertrand Coiffier, Hospices Civils de Lyon, Lyon; Franck Morschhauser, Hôpital Claude
Huriez, Centre Hospitalier Universitaire de Lille, Lille, France; Barbara Pro, Fox Chase …

PURPOSE Glofitamab is a T-cell–engaging bispecific antibody possessing a novel 2: 1
structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I …